Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130520 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer
A Phase 2 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00130520 is a Phase 2 study that has completed, run by University of Arizona. The registered enrollment target is 40 participants.
The verdict
NCT00130520, a Phase 2 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this project is to determine if a new combination of drugs, erlotinib (Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian cancer whose cancer has progressed while on prior standard chemotherapy treatment with a taxane (paclitaxel or docetaxel) and a platinum (cisplatin or carboplatin).
Interventions
- DRUG bevacizumab
- DRUG erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130520
The ClinicalTrials.gov registry entry for NCT00130520 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bevacizumab is the first listed.
NCT00130520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00130520 about?
NCT00130520 is a clinical study titled "Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer". The purpose of this project is to determine if a new combination of drugs, erlotinib (Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian cancer whose cancer has progressed while on prior standard chemotherapy treatment with a taxane (paclitaxel or docetaxel) an...
What is the current status of trial NCT00130520?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2005-06. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00130520?
The interventions under investigation include: bevacizumab (DRUG), erlotinib (DRUG).
Who is sponsoring clinical trial NCT00130520?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.